A Single Dose, Dose-escalating, Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of Intravesical Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer.
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2012
At a glance
- Drugs Urocanic acid (Primary) ; Urocanic acid (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jun 2012 Additional lead trial centre and investigators identified as reported by ClinicalTrials.gov.